ACT-462206

ACT-462206 is a dual orexin receptor antagonist (IC 50 for OX 1 = 60nM, OX 2 = 11nM) which has been investigated for the treatment of insomnia.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ACT-462206 is a dual orexin receptor antagonist (IC 50 for OX 1 = 60nM, OX 2 = 11nM) which has been investigated for the treatment of insomnia. In human trials, ACT-462206 produced dose-dependent sedative effects and was generally well tolerated, with residual sleepiness and headache being the most common adverse events.

Pharmacology

In humans, the sedative effects of ACT-462206 began 45 minutes after oral administration, and dissipated within 8 hours - consistent with a favorable pharmacodynamic profile for the treatment of insomnia. However, the pharmacokinetic profile of ACT-462206 diverges significantly from what would be expected based on behavioral effects.

Elevated plasma concentrations of ACT-462206 are sustained for over 24–36 hours after administration - despite behavioral measures of sedation disappearing within 8 hours of administration.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370718062 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.